新华时评·民生无小事丨惩治“阴阳价”！定点药店岂能“看人下菜碟”

Core Points - The article highlights the issue of "yin-yang pricing" in designated pharmacies, where the same cold medicine is priced differently for insured and uninsured customers, leading to significant price discrepancies [1] - It emphasizes the need for strict regulation and monitoring of pharmacies engaging in such practices to protect the integrity of the medical insurance fund and public trust in the healthcare system [1][2] Group 1 - The practice of "yin-yang pricing" is driven by pharmacies attempting to alleviate operational pressures by shifting costs onto insured patients, alongside a lack of transparency in drug pricing [1] - A recent notification has been issued to enhance monitoring and handling of "yin-yang pricing" in designated retail pharmacies, calling for serious investigations and penalties [1] - Measures against pharmacies practicing "yin-yang pricing" may include interviews, suspension of medical insurance settlements, and termination of medical service agreements, aiming to deter such illegal activities [1] Group 2 - To combat the "yin-yang pricing" phenomenon, there is a call for preventive measures, including the use of technology to create a comprehensive supervision network through drug price comparison apps and traceability codes [2] - The article stresses that the qualification for medical insurance designated pharmacies should not be seen as a license for unregulated practices but as a commitment to honest business operations [2] - The goal is to ensure fair and transparent drug purchasing, allowing the medical insurance fund to be utilized effectively, thereby increasing public confidence in the healthcare system [2]